Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.

在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化：Janice M. Mehnert 医学博士的 NCI 研究专家（临床科学家）奖申请

• 批准号: 10721095
• 负责人: Janice M. Mehnert
• 金额: $ 11.07万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-05 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10721095
• 关键词: American College of Radiology Imaging Network; Award; Cancer Center; Clinical Cancer Center; Clinical Research; Clinical Trials; Clinical Trials Network; Communication; Cutaneous; Disease Management; Doctor of Medicine; Early Therapeutic-Clinical Trials Network; Eastern Cooperative Oncology Group; Equity; Faculty; Funding; Future; Goals; Grant; Health; Hospitals; Information Technology; Infrastructure; Lead; Long Island; Medical Oncology; Medicine; Mentors; Mentorship; Mission; NCI Center for Cancer Research; National Clinical Trials Network; Oncology; Organizational Affiliation; Patients; Physician Executives; Population Programs; Precision medicine trial; Process; Protocols documentation; Publications; Publishing; Research; Research Activity; Research Infrastructure; Research Personnel; Resource Allocation; Resources; Rewards; Role; Scientist; Site; Skin; Specialist; Strategic Planning; Supervision; Time; Underserved Population; equity, diversity, and inclusion; ethnic diversity; improved; innovation; medical schools; melanoma; operation; patient oriented; phase I trial; process improvement; professor; racial diversity; recruit; screening; targeted cancer therapy; timeline

Janice M. Mehnert, M.D., is the Associate Director (AD) for Clinical Research, Director, Melanoma and Cutaneous Oncology and a tenured Professor of Medicine at the Perlmutter Cancer Center (PCC) of NYU Langone Health/NYU Grossman School of Medicine. Here, she engages in significant efforts to promote NCI-sponsored clinical research. She is active within NCI sponsored clinical trials networks, including the National Clinical Trials Network (NCTN), where she serves as the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) Melanoma and Skin Committee Co-Chair, and the Early Therapeutics Clinical Trials Network (ET-CTN), where she serves as site PI overseeing PCC’s ET-CTN clinical trial efforts. She has conducted and published multiple investigator initiated protocols, many with NCI support, and demonstrated a track record of mentoring junior investigators. As AD, Dr. Mehnert is responsible for the supervision of clinical trial operations in Manhattan, Long Island (LI), and Bellevue Hospital Center (overseeing site Medical Directors and Clinical Trials Office (CTO) Administrative Directors and staff), CTO resource allocation, prioritization of PCC’s research protocols and oversight of PCC’s 12 Disease Management Groups (DMGs). She also completes strategic planning for future clinical research activities including those at PCC’s Brooklyn campus. Since her recruitment to PCC, she has spearheaded the reorganization of the clinical research infrastructure, decreased trial activation timelines, and assembled resources to support Phase I trial activity at PCC-LI. She engaged PCC in NCI-sponsored initiatives to promote equitable access to clinical trials. She successfully competed for funding for the Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP) Program, which allowed her to rapidly activate 20 ET-CTN trials and assemble a prescreening infrastructure to navigate racially and ethnically diverse and underserved patients to ET-CTN protocols. She subsequently led the integration of PCC into the Dana Farber-Harvard Cancer Center Lead Academic Organization (UM1CA186709) as an Affiliate Organization. In this application, she outlines plans to 1) Promote opportunities for PCC investigators to lead NCI- sponsored clinical trials; 2) Promote accrual to NCI sponsored trials, including the submission of a NCTN Lead Academic Participating Site (LAPS) grant, 3) Promote equitable access to clinical trials and 4) Promote equitable access to research opportunities. She also outlines plans to improve communication of trial offerings, increase access to precision medicine trials, and develop information technology approaches to streamline research processes. The R50 Clinical Research Specialist Award would allow PCC to protect Dr. Mehnert’s time to pursue these research activities. Her accomplishment of these goals will increase access for PCC investigators and PCC patients to NCI sponsored trials and clinical research opportunities, a significant reward for the PCC clinical research enterprise and the NCI clinical research mission.

Janice M. Mehnert 医学博士是临床研究副主任 (AD)、黑色素瘤和 纽约大学珀尔穆特癌症中心 (PCC) 皮肤肿瘤学和医学终身教授 兰格健康中心/纽约大学格罗斯曼医学院在这里，她做出了巨大的努力来促进。 她积极参与 NCI 资助的临床试验网络，包括 国家临床试验网络 (NCTN)，她担任东部肿瘤合作组织 美国放射影像学院团体 (ECOG-ACRIN) 黑色素瘤和皮肤委员会 早期治疗临床试验网络 (ET-CTN) 联合主席，她担任现场 PI 她负责监督 PCC 的 ET-CTN 临床试验工作，并发表了多名研究人员的论文。 发起了协议，其中许多都得到了 NCI 的支持，并展示了指导初级研究人员的记录。 作为 AD，Mehnert 博士负责监督长岛曼哈顿 (LI) 的临床试验运营， 和贝尔维尤医院中心（监督现场医疗主任和临床试验办公室 (CTO) 行政 董事和员工）、CTO 资源分配、PCC 研究方案的优先顺序以及 PCC 的监督 她还完成了 12 个疾病管理小组 (DMG) 的未来临床研究战略规划。 自从加入 PCC 以来，她一直带头开展这些活动，包括在 PCC 布鲁克林校区的活动。 重组临床研究基础设施，缩短试验启动时间，并组装 她让 PCC 参与 NCI 发起的促进活动。 她成功地竞争了“创建有针对性的机会”的资金。 服务不足人群癌症治疗 (CATCH-UP) 计划，使她能够快速激活 20 ET-CTN 进行试验并组建预筛选基础设施，以适应不同种族和民族的需求 她随后领导将 PCC 纳入 Dana。 法伯-哈佛癌症中心领导学术组织 (UM1CA186709) 作为附属组织。 在这份申请中，她概述了以下计划： 1) 为 PCC 调查人员提供领导 NCI 的机会 赞助的临床试验；2) 促进 NCI 赞助的试验的累积，包括提交 NCTN 主要学术参与站点 (LAPS) 拨款，3) 促进公平地参与临床试验，4) 她还概述了改善沟通的计划。 试验产品、增加精准医学试验的机会并开发信息技术 R50 临床研究专家奖将允许 PCC 简化研究流程。 保护 Mehnert 博士从事这些研究活动的时间，她对这些目标的实现将会增加。 PCC 研究人员和 PCC 患者能够获得 NCI 赞助的试验和临床研究机会， 对PCC临床研究企业和NCI临床研究任务的重大奖励。